Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec;71(12):3340-3350.
doi: 10.1093/jac/dkw338. Epub 2016 Sep 1.

A review of treatment modalities for Middle East Respiratory Syndrome

Yin Mo  1   2 , Dale Fisher  3   4
Affiliations
Review

A review of treatment modalities for Middle East Respiratory Syndrome

Yin Mo et al. J Antimicrob Chemother. 2016 Dec.

Abstract

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been a focus of international attention since its identification in 2012. Epidemiologically it is characterized by sporadic community cases, which are amplified by hospital-based outbreaks. Healthcare facilities in 27 countries from most continents have experienced imported cases, with the most significant outbreak involving 186 cases in Korea. The mortality internationally is 36% and guidance for clinical management has yet to be developed. Most facilities and healthcare providers outside of the Middle East receiving patients have no or little experience in the clinical management of MERS. When a case does occur there is likely little time for a critical appraisal of the literature and putative pharmacological options. We identified published literature on the management of both MERS-CoV and the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) through searches of PubMed and WHO and the US CDC websites up to 30 April 2016. A total of 101 publications were retrieved for critical appraisal. Most published literature on therapeutics for MERS are in vitro experiments, animal studies and case reports. Current treatment options for MERS can be categorized as: immunotherapy with virus-specific antibodies in convalescent plasma; polyclonal and monoclonal antibodies produced in vitro or in genetically modified animals; and antiviral agents. The use of any therapeutics in MERS-CoV remains investigational. The therapeutic agents with potential benefits and warranting further investigation include convalescent plasma, interferon-β/ribavirin combination therapy and lopinavir. Corticosteroids, ribavirin monotherapy and mycophenolic acid likely have toxicities that exceed potential benefits.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): MERS-CoV in Republic Korea at a Glance. http://www.wpro.who.int/outbreaks_emergencies/wpro_coronavirus/en.
    1. Zumla A, Chan JF, Azhar EI et al. . Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327–47. - PMC - PubMed
    1. Al Ghamdi M, Alghamdi KM, Ghandoora Y et al. . Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC Infect Dis 2016; 16: 174. - PMC - PubMed
    1. Song W, Wang Y, Wang N et al. . Identification of residues on human receptor DPP4 critical for MERS-CoV binding and entry. Virology 2014; 471–473: 49–53. - PMC - PubMed
    1. Raj VS, Mou H, Smits SL et al. . Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495: 251–4. - PMC - PubMed

MeSH terms